Barinthus Biotherapeutics plc (BRNS) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.58
• Market Cap: $24.91M
• EPS: $-1.88
• 52-Week High: $2.91
• 52-Week Low: $0.56

About Barinthus Biotherapeutics plc

Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company based in Harwell, United Kingdom, dedicated to pioneering T cell immunotherapeutics that strengthen the immune response against chronic infectious diseases, autoimmune disorders, and various cancers. With a strong emphasis on innovative research and development, Barinthus seeks to transform the treatment landscape through targeted immunotherapies that address pressing health challenges. As it advances its portfolio of...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Barinthus Biotherapeutics plc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does BRNS pay dividends?

Barinthus Biotherapeutics plc (BRNS) does not currently pay a regular dividend.

What is BRNS's market cap?

Barinthus Biotherapeutics plc (BRNS) has a market capitalization of $24.91M with a current stock price of $0.58.